SCHEMBL31678102

SCHEMBL31678102

CCc1nc2n(CC(=O)Nc3ccc(C(F)(F)F)cc3)c(C)c(Br)n2c(=O)c1-c1ccccc1N

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ AKR1B1 P15121 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TPSAB1 Q15661 1/20 0.37
▸ TRPA1 O75762 1/20 0.37
▸ FPR2 P25090 3/20 0.36
▸ FPR1 P21462 2/20 0.36
▸ KCNJ5 P48544 1/20 0.36
▸ KCNJ3 P48549 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ BCHE P06276 2/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31678727 0.94 AKR1B1 (0.41) KDM4EAKR1B1MAPTTP53TRPA1
SCHEMBL31678790 0.89 AKR1B1 (0.40) KDM4EAKR1B1MAPTTP53TRPA1
SCHEMBL31653720 0.88 ALDH1A1 (0.42) KDM4EAKR1B1MAPTTP53TRPA1
SCHEMBL31678064 0.88 KDM4E (0.38) KDM4EAKR1B1MAPTTRPA1FPR2
SCHEMBL31678236 0.86 KDM4E (0.39) KDM4EAKR1B1MAPTTRPA1FPR2
SCHEMBL31678252 0.86 KDM4E (0.40) KDM4EAKR1B1MAPTTP53TPSAB1
SCHEMBL31677892 0.85 KDM4E (0.43) KDM4EAKR1B1MAPTTP53TRPA1
SCHEMBL31677806 0.84 AKR1B1 (0.40) KDM4EAKR1B1MAPTTP53TRPA1
SCHEMBL31664558 0.84 AKR1B1 (0.42) KDM4EAKR1B1MAPTTP53TRPA1
SCHEMBL31664550 0.84 AKR1B1 (0.42) KDM4EAKR1B1MAPTTP53TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 2390/4885AKR1B1 2548/4885MAPT 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback